{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:33:41Z","timestamp":1783038821843,"version":"3.54.6"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Soft tissue sarcomas (STS) represent a diverse group of rare malignant tumors. Currently, five to six weeks of preoperative radiotherapy (RT) combined with surgery  constitute the mainstay of therapy for localized high-grade sarcomas (G2\u2013G3). Growing evidence suggests that shortening preoperative RT courses by hypofractionation neither increases toxicity rates nor impairs oncological outcomes. Instead, shortening RT courses may improve therapy adherence, raise cost-effectiveness, and provide more treatment opportunities for a wider range of patients. Presumed higher rates of adverse effects and worse outcomes are concerns about hypofractionated RT (HFRT) for STS. This systematic review summarizes the current evidence on preoperative HFRT for the treatment of STS and discusses toxicity and oncological outcomes compared to normofractionated RT.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a systematic review of clinical trials describing outcomes for preoperative HFRT in the management of STS using PubMed, the Cochrane library, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Embase, and Ovid Medline. We followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Trials on retroperitoneal sarcomas, postoperative RT, and hyperthermia were excluded. Articles published until November 30th, 2021, were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Initial search yielded 94 articles. After removal of duplicate and ineligible articles, 13 articles qualified for analysis. Eight phase II trials and five retrospective analyses were reviewed. Most trials applied 5\u2009\u00d7\u20095\u00a0Gy preoperatively in patients with high-grade STS. HFRT courses did not show increased rates of adverse events compared to historical trials of normofractionated RT. Toxicity rates were mostly comparable or lower than in trials of normofractionated RT. Moreover, HFRT achieved comparable local control rates with shorter duration of therapy. Currently, more than 15 prospective studies on HFRT\u2009+\u2009\/\u2009\u2212\u2009chemotherapy are ongoing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Retrospective data and phase II trials suggest preoperative HFRT to be a reasonable treatment modality for STS. Oncological outcomes and toxicity profiles were favorable. To date, our knowledge is mostly derived from phase II data. No randomized phase III trial comparing normofractionated and HFRT in STS has been published yet. Multiple ongoing phase II trials applying HFRT to investigate acute and late toxicity will hopefully bring forth valuable findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02072-9","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T10:05:35Z","timestamp":1663149935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-4994","authenticated-orcid":false,"given":"Siyer","family":"Roohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-1755","authenticated-orcid":false,"given":"Felix","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kobus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fl\u00f6rcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"M\u00e4rdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana K\u00e4the","family":"Striefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"\u00d6llinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Jarosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Budach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-5629","authenticated-orcid":false,"given":"David","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"7","key":"2072_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701\u201311.","journal-title":"N Engl J Med"},{"key":"2072_CR2","unstructured":"Goldblum JR, Weiss SW, Folpe AL. Enzinger and Weiss's soft tissue tumors E-book: Elsevier Health Sciences;2013."},{"key":"2072_CR3","doi-asserted-by":"crossref","unstructured":"Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin N Am. 2008;88(3):451\u201381.","DOI":"10.1016\/j.suc.2008.03.006"},{"issue":"1","key":"2072_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2045-3329-2-14","volume":"2","author":"Z Burningham","year":"2012","unstructured":"Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14.","journal-title":"Clin Sarcoma Res"},{"issue":"8","key":"2072_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2014a population-based study. Lancet Oncol. 2017;18(8):1022\u201339.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2072_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijc.2910330108","volume":"33","author":"M Trojani","year":"1984","unstructured":"Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37\u201342.","journal-title":"Int J Cancer"},{"key":"2072_CR7","doi-asserted-by":"crossref","unstructured":"Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer. 1984;53(3):530\u201341.","DOI":"10.1002\/1097-0142(19840201)53:3<530::AID-CNCR2820530327>3.0.CO;2-D"},{"key":"2072_CR8","unstructured":"WHO. Classification of tumors, Soft tissue and bone tumours 5th Edition ed. Lyon: International Agency for Research on Cancer;2020."},{"issue":"4","key":"2072_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/CCO.0000000000000377","volume":"29","author":"WJ van Houdt","year":"2017","unstructured":"van Houdt WJ, Zaidi S, Messiou C, Thway K, Strauss DC, Jones RL. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017;29(4):260\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"2072_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-011-0144-6","volume":"12","author":"LH Lindner","year":"2011","unstructured":"Lindner LH, Issels RD. Hyperthermia in soft tissue sarcoma. Curr Treat Options Oncol. 2011;12(1):12\u201320.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"2072_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1200\/JCO.1996.14.5.1679","volume":"14","author":"PW Pisters","year":"1996","unstructured":"Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679\u201389.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2072_CR12","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1002\/cncr.27639","volume":"118","author":"DJ Biau","year":"2012","unstructured":"Biau DJ, Ferguson PC, Chung P, Griffin AM, Catton CN, O\u2019Sullivan B, et al. Local recurrence of localized soft tissue sarcoma: a new look at old predictors. Cancer. 2012;118(23):5867\u201377.","journal-title":"Cancer"},{"issue":"5","key":"2072_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671\u201380.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2072_CR14","first-page":"218","volume":"237","author":"FC Eilber","year":"2003","unstructured":"Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237(2):218\u201326.","journal-title":"Ann Surg"},{"issue":"11","key":"2072_CR15","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1634\/theoncologist.2016-0498","volume":"22","author":"K Harati","year":"2017","unstructured":"Harati K, Goertz O, Pieper A, Daigeler A, Joneidi-Jafari H, Niggemann H, et al. Soft tissue sarcomas of the extremities: surgical margins can be close as long as the resected tumor has no ink on it. Oncologist. 2017;22(11):1400\u201310.","journal-title":"Oncologist"},{"issue":"1","key":"2072_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijrobp.2010.08.042","volume":"82","author":"KE Haglund","year":"2012","unstructured":"Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82(1):361\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2072_CR17","unstructured":"Deutsche Krebsgesellschaft DK, AWMF. S3-Leitlinie Adulte Weichgewebesarkome, Langversion Version 1.0, 2021. Leitlinienprogramm Onkologie. 2021."},{"issue":"11","key":"2072_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>\u2606<\/sup>. Ann Oncol. 2021;32(11):1348\u201365.","journal-title":"Ann Oncol"},{"issue":"7","key":"2072_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/annonc\/mdz124","volume":"30","author":"JY Blay","year":"2019","unstructured":"Blay JY, Honor\u00e9 C, Stoeckle E, Meeus P, Jafari M, Gouin F, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019;30(7):1143\u201353.","journal-title":"Ann Oncol"},{"issue":"3","key":"2072_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijrobp.2012.01.062","volume":"84","author":"RL Haas","year":"2012","unstructured":"Haas RL, Delaney TF, O\u2019Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: Why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84(3):572\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2072_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/theoncologist.2017-0391","volume":"23","author":"C Rothermundt","year":"2018","unstructured":"Rothermundt C, Fischer GF, Bauer S, Blay JY, Gr\u00fcnwald V, Italiano A, et al. Pre- and postoperative chemotherapy in localized extremity soft tissue sarcoma: a European organization for research and treatment of cancer expert survey. Oncologist. 2018;23(4):461\u20137.","journal-title":"Oncologist"},{"issue":"6","key":"2072_CR22","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/j.prro.2017.04.010","volume":"7","author":"S Lazarev","year":"2017","unstructured":"Lazarev S, McGee H, Moshier E, Ru M, Demicco EG, Gupta V. Preoperative vs postoperative radiation therapy in localized soft tissue sarcoma: nationwide patterns of care and trends in utilization. Pract Radiat Oncol. 2017;7(6):e507\u201316.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2072_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.prro.2021.04.005","volume":"11","author":"KE Salerno","year":"2021","unstructured":"Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11(5):339\u201351.","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2072_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.020","volume":"75","author":"AM Davis","year":"2005","unstructured":"Davis AM, O\u2019Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48\u201353.","journal-title":"Radiother Oncol"},{"key":"2072_CR25","doi-asserted-by":"crossref","unstructured":"O'Sullivan B, Davis AM, Turcotte RE, Bell R, Wunder JS, Catton CN, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2004;22 14_suppl:9007.","DOI":"10.1200\/jco.2004.22.90140.9007"},{"issue":"9325","key":"2072_CR26","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O'Sullivan","year":"2002","unstructured":"O\u2019Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235\u201341.","journal-title":"Lancet"},{"issue":"2","key":"2072_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrc2587","volume":"9","author":"GC Barnett","year":"2009","unstructured":"Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134\u201342.","journal-title":"Nat Rev Cancer"},{"key":"2072_CR28","doi-asserted-by":"crossref","unstructured":"Wang K, Tepper JE. Radiation therapy-associated toxicity: Etiology, management, and prevention. CA A Cancer J Clin. 2021;71(5):437\u201354.","DOI":"10.3322\/caac.21689"},{"issue":"6","key":"2072_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513\u201320.","journal-title":"N Engl J Med"},{"issue":"10196","key":"2072_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395.","journal-title":"Lancet"},{"issue":"11","key":"2072_CR31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086\u201394.","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"2072_CR32","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.21037\/cco.2017.06.19","volume":"6","author":"L Ma","year":"2017","unstructured":"Ma L, Wang L, Tseng CL, Sahgal A. Emerging technologies in stereotactic body radiotherapy. Chin Clin Oncol. 2017;6(Suppl 2):S12.","journal-title":"Chin Clin Oncol"},{"key":"2072_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7765","volume":"345","author":"SS Ahmad","year":"2012","unstructured":"Ahmad SS, Duke S, Jena R, Williams MV, Burnet NG. Advances in radiotherapy. BMJ Br Med J. 2012;345: e7765.","journal-title":"BMJ Br Med J"},{"key":"2072_CR34","unstructured":"Advanced and emerging technologies in radiation oncology physics. [s.l.]: CRC Press;2020."},{"issue":"20","key":"2072_CR35","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1200\/JCO.2014.58.5828","volume":"33","author":"D Wang","year":"2015","unstructured":"Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015;33(20):2231\u20138.","journal-title":"J Clin Oncol"},{"key":"2072_CR36","doi-asserted-by":"crossref","unstructured":"van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):96.","DOI":"10.1186\/s13014-018-1040-z"},{"issue":"4","key":"2072_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0360-3016(86)90081-7","volume":"12","author":"HD Thames","year":"1986","unstructured":"Thames HD, Suit HD. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys. 1986;12(4):687\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2072_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1667\/RADE-20-00226.1","volume":"196","author":"RL Haas","year":"2021","unstructured":"Haas RL, Floot BGJ, Scholten AN, van der Graaf WTA, van Houdt W, Schrage Y, et al. Cellular radiosensitivity of soft tissue sarcoma. Radiat Res. 2021;196(1):23\u201330.","journal-title":"Radiat Res"},{"issue":"9618","key":"2072_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"SM Bentzen","year":"2008","unstructured":"Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098\u2013107.","journal-title":"Lancet"},{"issue":"10","key":"2072_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215\u201323.","journal-title":"Br J Surg"},{"issue":"7","key":"2072_CR41","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/jso.25052","volume":"117","author":"T Abarca","year":"2018","unstructured":"Abarca T, Gao Y, Monga V, Tanas MR, Milhem MM, Miller BJ. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol. 2018;117(7):1479\u201386.","journal-title":"J Surg Oncol"},{"issue":"4","key":"2072_CR42","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2017.12.262","volume":"100","author":"S Venigalla","year":"2018","unstructured":"Venigalla S, Nead KT, Sebro R, Guttmann DM, Sharma S, Simone CB 2nd, et al. Association between treatment at high-volume facilities and improved overall survival in soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2018;100(4):1004\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2072_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2019.01.005","volume":"110","author":"M Vos","year":"2019","unstructured":"Vos M, Blaauwgeers HGT, Ho VKY, van Houdt WJ, van der Hage JA, Been LB, et al. Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands. Eur J Cancer. 2019;110:98\u2013106.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2072_CR44","first-page":"223","volume":"23","author":"MR Pfeffer","year":"2017","unstructured":"Pfeffer MR, Blumenfeld P. The changing paradigm of radiotherapy in the elderly population. Cancer J. 2017;23(4):223\u201330.","journal-title":"Cancer J"},{"issue":"11","key":"2072_CR45","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41585-021-00498-6","volume":"18","author":"M Yan","year":"2021","unstructured":"Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, et al. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol. 2021;18(11):669\u201385.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"2072_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ijrobp.2010.11.077","volume":"82","author":"DJ Hoopes","year":"2012","unstructured":"Hoopes DJ, Kaziska D, Chapin P, Weed D, Smith BD, Hale ER, et al. Patient preferences and physician practice patterns regarding breast radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(2):674\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2072_CR47","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-19-3524","volume":"26","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, et al. A Phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma. Clin Cancer Res. 2020;26(8):1829\u201336.","journal-title":"Clin Cancer Res"},{"key":"2072_CR48","doi-asserted-by":"crossref","unstructured":"Zempl\u00e9nyi AT, Kal\u00f3 Z, Kov\u00e1cs G, Farkas R, Be\u00f6the T, B\u00e1nyai D, et al. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl). 2018;27(1).","DOI":"10.1111\/ecc.12430"},{"issue":"3","key":"2072_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.adro.2017.07.010","volume":"2","author":"KR Voong","year":"2017","unstructured":"Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, et al. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017;2(3):249\u201358.","journal-title":"Adv Radiat Oncol"},{"key":"2072_CR50","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3389\/fonc.2020.00993","volume":"10","author":"MJ Spa\u0142ek","year":"2020","unstructured":"Spa\u0142ek MJ, Rutkowski P. Coronavirus disease (COVID-19) outbreak: hypofractionated radiotherapy in soft tissue sarcomas as a valuable option in the environment of limited medical resources and demands for increased protection of patients. Front Oncol. 2020;10:993.","journal-title":"Front Oncol"},{"key":"2072_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2072_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"2072_CR53","doi-asserted-by":"crossref","unstructured":"Kose\u0142a-Paterczyk H, Teterycz P, Spa\u0142ek MJ, Borkowska A, Zawadzka A, W\u0105grodzki M, et al. Efficacy and safety of hypofractionated preoperative radiotherapy for primary locally advanced soft tissue sarcomas of limbs or trunk wall. Cancers (Basel). 2021;13(12).","DOI":"10.3390\/cancers13122981"},{"issue":"4","key":"2072_CR54","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.ijrobp.2021.02.019","volume":"110","author":"MJ Spa\u0142ek","year":"2021","unstructured":"Spa\u0142ek MJ, Kose\u0142a-Paterczyk H, Borkowska A, W\u0105grodzki M, Szumera-Cie\u0107kiewicz A, Czarnecka AM, et al. Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: results of a phase 2 clinical trial. Int J Radiat Oncol Biol Phys. 2021;110(4):1053\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2072_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.radonc.2021.06.027","volume":"161","author":"ETT Leite","year":"2021","unstructured":"Leite ETT, Munhoz RR, Camargo VP, Lima L, Rebolledo DCS, Maistro CEB, et al. Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. Radiother Oncol. 2021;161:222\u20139.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2072_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2478\/raon-2021-0038","volume":"55","author":"V Potkrajcic","year":"2021","unstructured":"Potkrajcic V, Traub F, Hermes B, Scharpf M, Kolbenschlag J, Zips D, et al. Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population. Radiol Oncol. 2021;55(4):459\u201366.","journal-title":"Radiol Oncol"},{"key":"2072_CR57","doi-asserted-by":"crossref","unstructured":"Gobo Silva ML, Lopes de Mello CA, Aguiar Junior S, D'Almeida Costa F, Stevanato Filho PR, Santoro Bezerra T, et al. Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: safety, feasibility, and early oncologic outcomes of a phase 2 trial. Radiother Oncol. 2021;159:161\u20137.","DOI":"10.1016\/j.radonc.2021.03.033"},{"key":"2072_CR58","doi-asserted-by":"crossref","unstructured":"Kose\u0142a-Paterczyk H, Spa\u0142ek M, Borkowska A, Teterycz P, W\u0105grodzki M, Szumera-Cie\u0107kiewicz A, et al. Hypofractionated radiotherapy in locally advanced myxoid liposarcomas of extremities or trunk wall: results of a single-arm prospective clinical trial. J Clin Med. 2020;9(8).","DOI":"10.3390\/jcm9082471"},{"issue":"6","key":"2072_CR59","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.adro.2020.06.024","volume":"5","author":"S Parsai","year":"2020","unstructured":"Parsai S, Lawrenz J, Kilpatrick S, Rubin B, Hymes C, Gray M, et al. Early outcomes of preoperative 5-fraction radiation therapy for soft tissue sarcoma followed by immediate surgical resection. Adv Radiat Oncol. 2020;5(6):1274\u20139.","journal-title":"Adv Radiat Oncol"},{"issue":"12","key":"2072_CR60","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/COC.0000000000000443","volume":"41","author":"JD Pennington","year":"2018","unstructured":"Pennington JD, Eilber FC, Eilber FR, Singh AS, Reed JP, Chmielowski B, et al. Long-term outcomes with ifosfamide-based hypofractionated preoperative chemoradiotherapy for extremity soft tissue sarcomas. Am J Clin Oncol. 2018;41(12):1154\u201361.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2072_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/COC.0000000000000236","volume":"41","author":"GJ Kubicek","year":"2018","unstructured":"Kubicek GJ, LaCouture T, Kaden M, Kim TW, Lerman N, Khrizman P, et al. Preoperative radiosurgery for soft tissue sarcoma. Am J Clin Oncol. 2018;41(1):86\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2072_CR62","first-page":"60","volume":"21","author":"L K\u0131l\u0131\u00e7","year":"2017","unstructured":"K\u0131l\u0131\u00e7 L, Ekenel M, Karabulut S, A\u011fao\u011flu F, Darendeliler E. Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience. Contemp Oncol (Pozn). 2017;21(1):60\u20135.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"2072_CR63","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ejso.2016.02.258","volume":"42","author":"H Kose\u0142a-Paterczyk","year":"2016","unstructured":"Kose\u0142a-Paterczyk H, Szumera-Cie\u0107kiewicz A, Szacht M, Haas R, Morysi\u0144ski T, Dziewirski W, et al. Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. Eur J Surg Oncol. 2016;42(6):891\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"2072_CR64","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.ejso.2014.05.016","volume":"40","author":"H Kose\u0142a-Paterczyk","year":"2014","unstructured":"Kose\u0142a-Paterczyk H, Szacht M, Morysi\u0144ski T, \u0141ugowska I, Dziewirski W, Falkowski S, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014;40(12):1641\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2072_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5865","volume":"7","author":"J Lansu","year":"2021","unstructured":"Lansu J, Bov\u00e9e J, Braam P, van Boven H, Flucke U, Bonenkamp JJ, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol. 2021;7(1): e205865.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2072_CR66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejso.2018.09.001","volume":"45","author":"J Lansu","year":"2019","unstructured":"Lansu J, Groenewegen J, van Coevorden F, van Houdt W, van Akkooi ACJ, van Boven H, et al. Time dependent dynamics of wound complications after preoperative radiotherapy in extremity soft tissue sarcomas. Eur J Surg Oncol. 2019;45(4):684\u201390.","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"2072_CR67","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/cncr.27951","volume":"119","author":"B O'Sullivan","year":"2013","unstructured":"O\u2019Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878\u201384.","journal-title":"Cancer"},{"issue":"10","key":"2072_CR68","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ejso.2006.04.003","volume":"32","author":"AC Hui","year":"2006","unstructured":"Hui AC, Ngan SY, Wong K, Powell G, Choong PF. Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol. 2006;32(10):1159\u201364.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2072_CR69","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2005.02.5577","volume":"24","author":"WG Kraybill","year":"2006","unstructured":"Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24(4):619\u201325.","journal-title":"J Clin Oncol"},{"key":"2072_CR70","doi-asserted-by":"crossref","unstructured":"Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003;56(2):482\u20138.","DOI":"10.1016\/S0360-3016(02)04510-8"},{"issue":"3","key":"2072_CR71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0360-3016(98)00277-6","volume":"42","author":"A Pollack","year":"1998","unstructured":"Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys. 1998;42(3):563\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2072_CR72","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.rpor.2020.07.003","volume":"25","author":"M Mayinger","year":"2020","unstructured":"Mayinger M, Straube C, Habermehl D, Duma MN, Combs SE. Hypo- vs. normofractionated radiation therapy in breast cancer: a patterns of care analysis in German speaking countries. Rep Pract Oncol Radiother. 2020;25(5):775\u20139.","journal-title":"Rep Pract Oncol Radiother."},{"issue":"5","key":"2072_CR73","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ijrobp.2014.10.028","volume":"90","author":"YM Mowery","year":"2014","unstructured":"Mowery YM, Blitzblau RC. Whole-breast radiation therapy: the long and short of it. Int J Radiat Oncol Biol Phys. 2014;90(5):990\u20132.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2072_CR74","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S0959-8049(01)00191-5","volume":"37","author":"CM Wendtner","year":"2001","unstructured":"Wendtner CM, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, et al. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer. 2001;37(13):1609\u201316.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2072_CR75","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/BF01613220","volume":"117","author":"RD Issels","year":"1991","unstructured":"Issels RD, Mitterm\u00fcller J, Gerl A, Simon W, Ortmaier A, Denzlinger C, et al. Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. J Cancer Res Clin Oncol. 1991;117(4):S141\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"2072_CR76","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0959-8049(01)00183-6","volume":"37","author":"RD Issels","year":"2001","unstructured":"Issels RD, Abdel-Rahman S, Wendtner CM, Falk MH, Kurze V, Sauer H, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer. 2001;37(13):1599\u2013608.","journal-title":"Eur J Cancer"},{"issue":"14","key":"2072_CR77","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1200\/JCO.2002.07.146","volume":"20","author":"CM Wendtner","year":"2002","unstructured":"Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20(14):3156\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2072_CR78","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1200\/JCO.1990.8.11.1818","volume":"8","author":"RD Issels","year":"1990","unstructured":"Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol. 1990;8(11):1818\u201329.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2072_CR79","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","volume":"4","author":"RD Issels","year":"2018","unstructured":"Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483\u201392.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2072_CR80","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","volume":"11","author":"RD Issels","year":"2010","unstructured":"Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem B-C, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561\u201370.","journal-title":"Lancet Oncol"},{"key":"2072_CR81","doi-asserted-by":"crossref","unstructured":"Spa\u0142ek MJ, Borkowska AM, Telejko M, W\u0105grodzki M, Nieby\u0142owska D, Uzar A, et al. The feasibility study of hypofractionated radiotherapy with regional hyperthermia in soft tissue sarcomas. Cancers (Basel). 2021;13(6).","DOI":"10.3390\/cancers13061332"},{"issue":"5","key":"2072_CR82","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1245\/s10434-012-2797-1","volume":"20","author":"EH Baldini","year":"2013","unstructured":"Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, et al. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol. 2013;20(5):1494\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2072_CR83","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1007\/s11999-013-3130-4","volume":"471","author":"A Schwartz","year":"2013","unstructured":"Schwartz A, Rebecca A, Smith A, Casey W, Ashman J, Gunderson L, et al. Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas. Clin Orthop Relat Res. 2013;471(11):3612\u20137.","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"2072_CR84","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.bjps.2019.05.041","volume":"72","author":"J Slump","year":"2019","unstructured":"Slump J, Bastiaannet E, Halka A, Hoekstra HJ, Ferguson PC, Wunder JS, et al. Risk factors for postoperative wound complications after extremity soft tissue sarcoma resection: a systematic review and meta-analyses. J Plast Reconstr Aesthet Surg. 2019;72(9):1449\u201364.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"3","key":"2072_CR85","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/CORR.0000000000000959","volume":"478","author":"M Bedi","year":"2020","unstructured":"Bedi M, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, et al. Is a nomogram able to predict postoperative wound complications in localized soft-tissue sarcomas of the extremity? Clin Orthop Relat Res. 2020;478(3):550\u20139.","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2072_CR86","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s10147-014-0717-z","volume":"19","author":"CW Song","year":"2014","unstructured":"Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014;19(4):570\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"17","key":"2072_CR87","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.7150\/jca.44408","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Shen L. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. J Cancer. 2020;11(17):5056\u201368.","journal-title":"J Cancer"},{"issue":"2","key":"2072_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/100.2.397","volume":"100","author":"CW Song","year":"1971","unstructured":"Song CW, Levitt SH. Vascular changes in walker 256 carcinoma of rats following X irradiation. Radiology. 1971;100(2):397\u2013407.","journal-title":"Radiology"},{"key":"2072_CR89","unstructured":"Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy. https:\/\/ClinicalTrials.gov\/show\/NCT04330456."},{"issue":"2","key":"2072_CR90","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ijrobp.2004.03.009","volume":"60","author":"G Pitson","year":"2004","unstructured":"Pitson G, Robinson P, Wilke D, Kandel RA, White L, Griffin AM, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2004;60(2):522\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2072_CR91","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13566-012-0085-0","volume":"2","author":"A Betgen","year":"2013","unstructured":"Betgen A, Haas RL, Sonke JJ. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol. 2013;2(1):55\u201362.","journal-title":"J Radiat Oncol"},{"key":"2072_CR92","unstructured":"Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas. https:\/\/ClinicalTrials.gov\/show\/NCT02106312."},{"key":"2072_CR93","unstructured":"Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas. https:\/\/ClinicalTrials.gov\/show\/NCT05109494."},{"issue":"10","key":"2072_CR94","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/cncr.11365","volume":"97","author":"GK Zagars","year":"2003","unstructured":"Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530\u201343.","journal-title":"Cancer"},{"issue":"23","key":"2072_CR95","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1002\/cncr.27639","volume":"118","author":"DJ Biau","year":"2012","unstructured":"Biau DJ, Ferguson PC, Chung P, Griffin AM, Catton CN, O\u2019Sullivan B, et al. Local recurrence of localized soft tissue sarcoma. Cancer. 2012;118(23):5867\u201377.","journal-title":"Cancer"},{"issue":"2","key":"2072_CR96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193\u2013201.","journal-title":"Oncologist"},{"issue":"29","key":"2072_CR97","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.2013.53.9452","volume":"32","author":"MR Folkert","year":"2014","unstructured":"Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32(29):3236\u201341.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2072_CR98","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1200\/JCO.2008.16.6249","volume":"26","author":"KM Alektiar","year":"2008","unstructured":"Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008;26(20):3440\u20134.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2072_CR99","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1001\/jama.1991.03470240055032","volume":"266","author":"DA Lazovich","year":"1991","unstructured":"Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA. 1991;266(24):3433\u20138.","journal-title":"JAMA"},{"issue":"14","key":"2072_CR100","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1002\/cncr.24375","volume":"115","author":"PW Chung","year":"2009","unstructured":"Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009;115(14):3254\u201361.","journal-title":"Cancer"},{"key":"2072_CR101","unstructured":"Board WCoTE. Soft Tissue and Bone Tumours: International Agency for Research on Cancer; 2020."},{"issue":"1","key":"2072_CR102","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.radonc.2015.12.002","volume":"119","author":"RL Haas","year":"2016","unstructured":"Haas RL, Miah AB, LePechoux C, DeLaney TF, Baldini EH, Alektiar K, et al. Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiother Oncol. 2016;119(1):14\u201321.","journal-title":"Radiother Oncol"},{"key":"2072_CR103","unstructured":"Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas."},{"key":"2072_CR104","unstructured":"Hypofractionated Radiation Therapy Before Surgery for the Treatment of Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk. https:\/\/ClinicalTrials.gov\/show\/NCT04562480."},{"key":"2072_CR105","unstructured":"Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk."},{"key":"2072_CR106","unstructured":"Pre-operative RadiothErapy for Soft Tissue SarcOmas. https:\/\/ClinicalTrials.gov\/show\/NCT04617327."},{"key":"2072_CR107","unstructured":"Hypofractionated Radiotherapy for Soft Tissue Sarcomas. https:\/\/ClinicalTrials.gov\/show\/NCT03972930."},{"key":"2072_CR108","unstructured":"Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions. https:\/\/ClinicalTrials.gov\/show\/NCT04946357."},{"key":"2072_CR109","unstructured":"Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion. https:\/\/ClinicalTrials.gov\/show\/NCT04219202."}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02072-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T13:32:53Z","timestamp":1664976773000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02072-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02072-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the nature of this paper and its methodology, no institutional review board approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}